Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More

Ajanta Pharma Q3 PAT may dip 35.1% YoY to Rs. 95.8 cr: ICICI Direct

Net Sales are expected to decrease by 11 percent Y-o-Y (down 3.9 percent Q-o-Q) to Rs. 522.6 crore, according to ICICI Direct.

January 11, 2019 / 05:01 PM IST
Shivalik Rasayan

Shivalik Rasayan

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

ICICI Direct has come out with its third quarter (October-December’ 18) earnings estimates for the Healthcare sector. The brokerage house expects Ajanta Pharma to report net profit at Rs. 95.8 crore down 35.1% year-on-year (down 23.6% quarter-on-quarter).


Net Sales are expected to decrease by 11 percent Y-o-Y (down 3.9 percent Q-o-Q) to Rs. 522.6 crore, according to ICICI Direct.


Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 32.8 percent Y-o-Y (down 20.1 percent Q-o-Q) to Rs. 132.7 crore.


Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Moneycontrol News

stay updated

Get Daily News on your Browser
Sections